Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis.
Campbell JR, Brode SK, Barry P, Bastos ML, Bonnet M, Guglielmetti L, Kempker R, Klimuk D, Laniado Laborín R, Milanov V, Singla R, Skrahina A, Trajman A, van der Werf TS, Viiklepp P, Menzies D. Campbell JR, et al. Thorax. 2024 Jan 18;79(2):169-178. doi: 10.1136/thorax-2023-220249. Thorax. 2024. PMID: 38135489
Combined cerebrospinal fluid metabolomic and cytokine profiling in tuberculosis meningitis reveals robust and prolonged changes in immunometabolic networks.
Tomalka J, Sharma A, Smith AGC, Avaliani T, Gujabidze M, Bakuradze T, Sabanadze S, Jones DP, Avaliani Z, Kipiani M, Kempker RR, Collins JM. Tomalka J, et al. Among authors: kempker rr. Tuberculosis (Edinb). 2024 Jan;144:102462. doi: 10.1016/j.tube.2023.102462. Epub 2023 Dec 2. Tuberculosis (Edinb). 2024. PMID: 38070353 Free PMC article.
Reply to Upton et al.
Kempker RR, Kipiani M, Peloquin CA. Kempker RR, et al. Clin Infect Dis. 2023 Jul 5;77(1):158-159. doi: 10.1093/cid/ciad188. Clin Infect Dis. 2023. PMID: 36978221 No abstract available.
Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
Mikiashvili L, Kempker RR, Chakhaia TS, Bablishvili N, Avaliani Z, Lomtadze N, Schechter MC, Kipiani M. Mikiashvili L, et al. Among authors: kempker rr. Clin Infect Dis. 2024 Apr 10;78(4):1043-1052. doi: 10.1093/cid/ciad694. Clin Infect Dis. 2024. PMID: 37962987 Free PMC article.
158 results